Bernstein 42nd Annual Strategic Decisions Conference May 27, 2026 11:00 AM EDTCompany ParticipantsJoaquin Duato - CEO ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Does prostate cancer screening save lives? The Cochrane, an influential group renowned for its gold-standard medical reviews, has previously addressed that question twice, and twice the answer was ‘no ...

Aglatimagene plus prodrug and standard of care EBRT significantly improved prostate cancer-specific DFS by 39% versus placebo in men with localized prostate cancer, especially those with ...

Primary results from the Phase II ARASEC trial show that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS ...

Ballot Babes — is breaking down city hall debates, municipal issues and council decisions in an effort to get people to the ...

WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...